Compare stocks

Basilea Pharmaceutica AG operates within the biopharmaceutical industry, focusing on the research, development, and commercialization of innovative medicines to meet medical needs in the areas of infectious diseases and oncology. The company's core products include anti-infective treatments such as Cresemba, an antifungal for invasive aspergillosis and mucormycosis, and Zevtera, a broad-spectrum antibiotic for bacterial infections. Founded in 2000 as a spin-off from Roche, the company is headquartered in Basel, Switzerland. Basilea's unique strategic approach involves enhancing its pipeline through collaborations and licensing agreements, which strengthens its position in the niche market of bacterial resistance and other medical areas with high unmet needs. The company has a significant presence in Europe, the United States, and Asia, expanding its commercial footprint globally.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.